Biochemical alterations in hepatocellular carcinoma patients treated with doxorubicin

Saber A.Sakr*, Nahed S.Bassely2, Mona A.Sakr3, Mahmoud Moawad3, Hassan M.Ahmed2
1Zoology Department, Faculty of Science, Menoufia University, Shebin El-kom, (EGYPT)
2National Organization for Drug control and Research, Cairo, (EGYPT)
3National Cancer Institute, Cairo University, Cairo, (EGYPT)
E-mail: sabsak@yahoo.com

ABSTRACT

Doxorubicin (Dox) is an anthracycline antibiotic used as a single chemotherapeutic agent for HCC and has been shown to produce a response rate of about 10-15% but with no proven survival benefits. The present work was conducted to study the biochemical alterations in HCC patients treated with doxorubicin. The study included 30 patients with a confirmed diagnosis of hepatocellular carcinoma (HCC). They were divided into 3 groups. Group 1. Ten specimens of heptocellular carcinoma patients were taken before doxorubicin treatments. Group 2. Ten specimens of heptocellular carcinoma patients were taken one week after doxorubicin treatment. Group 3. Ten specimens of heptocellular carcinoma patients were taken two weeks after doxorubicin treatment. Another ten normal volunteers were used as controls. Treatment schedule consists of i.v. injection of doxorubicin at a dose of 15 mg/m² weekly for 3 weeks. Ascitic fluid and blood serum were collected for biochemical examinations. The results showed that ascitic AFP, CEA, T.LDH and LDH4, LDH5 increased significantly in HCC patients. ALT, AST and ALP showed significant increase in sera of HCC patients. These biochemical parameters revealed significant decrease in Dox treated patients.

INTRODUCTION

Hepatocellular carcinoma (HCC) is one of the most common cancer worldwide. It accounts for more than 90% of all primary hepatic tumors[9] its incidence increases with age and is five times more common in men than in women[92]. HCC occurs as a complication of hepatic cirrhosis due to various etiologies. Early incidence of HCC in patients with cirrhosis is estimated to be around 3% to 5[14]. The hyperendemicity of hepatitis B virus infection in Africa and Asia explains the higher incidence of HCC in these regions compared to western countries[29]. Nonetheless, the incidence of HCC in western countries is expected to increase owing to the high prevalence of hepatitis C virus infection that represents a high risk factor for HCC[15].

The most commonly used single agents for HCC are the anthracyclines and anthraquinones, doxorubicin[4,12], 4’-epidoxorubicin[11], and mitoxantrone. Doxorubicin (Dox) is the first generation anthracycline anti-
Biochemical alterations in hepatocellular carcinoma patients treated...
significant increase in malignant group compared to the cases which used as control group (2.7 ± 1.8 ng / ml). The highest contribution was from the HCC before treatment which showed statistically significant increase (12.5 ± 4.7 ng/ml) compared to all other groups. The lower value was from the HCC after two weeks of treatment which showed statistically significant decrease (4.55 ± 2.11 ng /ml) compared to all other groups (figure 2).

Data regarding LDH and its isoenzymes of malignant and control cases were summarized in TABLE 1. Ascetic T.LDH and LDH4, LDH5 showed statistically significant increase in malignant group compared to the control cases. HCC cases before treatment showed statistically significant increase compared to all other groups. But the lower contribution was from the HCC after two weeks of treatment which showed statistically significant decrease compared to all other groups.

TABLE 1 : Change in total lactate dehydrogenase (T.LDH) and its isoenzymatic activities in different cases

<table>
<thead>
<tr>
<th>Treatment</th>
<th>T.LDH</th>
<th>LDH4</th>
<th>LDH5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>1.3±0.3</td>
<td>0.5±01</td>
<td>0.3±1</td>
</tr>
<tr>
<td>HCC group</td>
<td>196.5±27.9</td>
<td>26.6±3.7</td>
<td>21.7±2.1</td>
</tr>
<tr>
<td>HCC+1 weekDox</td>
<td>154.5±16.5*</td>
<td>23.9±3.2</td>
<td>20.6±2.1</td>
</tr>
<tr>
<td>HCC+2weekDox</td>
<td>97.8±23.8**</td>
<td>21.2±5.0*</td>
<td>14.8±6.7**</td>
</tr>
</tbody>
</table>

( * ) Significant at P<0.05, (**) Significant at P<0.001

Serum ALP, ALT and AST

In control groups, serum ALT and AST showed means of (32.7 ± 5.9 U / L) and (41.1 ± 9.8 U / L), respectively. These values showed a significant increase in HCC groups and the means of ALT and AST were (273.9 ±9.4 U / L) and (342.0 ± 45.3 U / L), respectively. On other hand, the activities of these enzymes decreased significantly in patients treated with Dox for two weeks (figures 3&4). Serum ALP showed statistically significant increase in HCC group compared to control cases. The activity of ALP significantly decreased after two weeks of HCC treatment (Figure 5).

DISCUSSION

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide,[30] ranks fifth in frequency worldwide among all malignancies and the third most common cause of cancer-related death. It causes one million deaths annually.[18] HCC comprises clinically che-
Biochemical alterations in hepatocellular carcinoma patients treated with chemotherapy resistant tumors, and this observation is supported by low response rates across a wide variety of cytotoxic agents. The most widely used agent has been doxorubicin, both as a single agent and in combination with other drugs. An early randomized trial against best supportive therapy showed slightly increased survival, in the order of weeks[23].

In the obtained result, ascitic AFP showed statistically significant increase in HCC group compared to control cases. This in agreement with Gadelhak et al.[7] who reported that concentration of AFP was greater than the upper reference limit indicate the presence of HCC, but values below this level are less useful because they may also occur in chronic liver disease. AFP is the most popular tumour marker for hepatocellular carcinoma (HCC). It is used in diagnosis and follows up of cases by estimating its rise. It was found that serum AFP level was elevated in 72.7% of HCC patients, and in ascitic fluid was elevated in 63.6%. Also, there was a highly significant, positive correlation between elevation of AFP in serum and in ascitic fluid (r = 0.778). Elevation of AFP in ascitic fluid is of high importance in evaluation of HCC and is as significant as serum and runs parallel to it. Estimation of AFP in ascitic fluid is much more significant in evaluation of HCC cases than ascitic fluid cytology[27]. This protein can directly diffuse from the liver towards the peritoneal cavity[36] and have molecular weight, around 70 kD. Thus, based on a possible release of AFP by the hepatic tumour directly into the ascitic fluid, Khakoo et al.[15] made the hypothesis that ascitic fluid AFP might have a better diagnostic value than serum AFP. A significant decrease in AFP was recorded in Dox-treated patients. Malagar et al.[19] reported that AFP levels decreased significantly in measurements 1 month post Dox-chemotherapy of HCC. Yau et al.[37] recorded that AFP response was defined as a relative drop of AFP >20% of the baseline level after sorafenib treatment. AFP-producing capacity of hepatoma cells can be changed by chemotherapeutic agents, probably through chromosomal mutation[22].

A significant increase in ascitic CEA was recorded in HCC patients compared with control cases. showed statistically significant increase in malignant group compared to the cases which used as control group. Sell[28] showed that CEA levels elevate in some patients with pathological conditions such as cirrhosis (45%), pulmonary emphysema (30%), rectal polyps (5%), benign breast disease (15%), and ulcerative colitis (15%). Recent evidence suggests that CEA is a cellular adhesion molecule that may potentiate invasion and metastasis. In this study, ascitic CEA level showed significantly decrease after Dox treatment. This study was recorded by Ku et al.[16] who said that a sharp decrease in serum CEA levels (to < 50% of their pretreatment levels) after Dox treatment.

The present results revealed significant higher levels of ascitic T.LDH in the HCC group compared to the control group. These results were in agreement with those of Gerbes et al.[8] and Castaldo et al.[3]. Glannoulaki et al.[10], showed that serum total LDH activity significantly increased in the non-malignant group and the malignant group compared to the control group. Ascetic LDH isoenzymes (LDH4 and LDH5) showed statistically significant increase in HCC group compared to the control cases. Zondag and Klein (1968) reported that one of the best characterized features of tumor growth is the associated alteration in the enzyme and isoenzyme pattern of tissues in the host organs. LDH is one of the enzyme system preferentially produced and retained by cancer cells, being necessary to maintain tumor growth. When LDH isoenzymes are released from neoplastic tissue in serum, the LDH isoenzymes pattern of the serum changes. Wilkinson[35] reported that elevation in LDH4 and LDH5 in malignant cases is due to re-emergence of foetal pattern of isoenzyme distribution i.e. to anaerobic (cathodal) isoenzyme which is a feature malignant transformation in many tissues. Ascetic T.LDH, LDH4 and LDH5 showed a significant decrease after Dox treatment. Similarly, Sun et al.[31] reported that LDH slowly decreased in HCC patients treated with tamoxifen, suggesting a slower, but continuous, progression of the disease after tamoxifen treatment.

Serum ALT and AST showed statistically significant increase in HCC group compared to control cases. This result was in agreement with Rosalki[26] who recorded that the AST and ALT levels are increased to some extent in almost all liver diseases such as viral hepatitis, drug or toxin induced hepatic necrosis and circulatory shock. Elevated plasma activities of AST or ALT are regarded as sensitive indicator of liver cells damage[5]. In this work, the lowest contribution of ALT and AST was from the HCC after Dox treatment. In
agreement of this result, Kazuhiro et al.\cite{14} showed that administration of rifampicin markedly decreased ALT and AST values in HCV-related liver cirrhosis patients with a high risk of HCC. Rifampicin has an anti-inflammatory effect on hepatocyte disorder by preventing the release of hepatic enzymes, including ALT and AST, and indirectly suppresses liver injury by inhibiting secretion of cytokines.

In present result, ALP showed statistically significant increase in HCC group compared to control cases. It has been recognized that a raised ALP level in the absence of jaundice, may be used as possible presumptive evidence of HCC\cite{13}. The activity of ALP decreased after two weeks of HCC treated with Dox. This result agrees with Mulders et al.\cite{21} who reported a decrease in ALP during the first months of chemotherapy treatment in HCC cases.

REFERENCES

Biochemical alterations in hepatocellular carcinoma patients treated


